1. Home
  2. TYGO vs ADCT Comparison

TYGO vs ADCT Comparison

Compare TYGO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tigo Energy Inc.

TYGO

Tigo Energy Inc.

HOLD

Current Price

$1.17

Market Cap

129.0M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.13

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYGO
ADCT
Founded
2007
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.0M
136.1M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
TYGO
ADCT
Price
$1.17
$1.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$6.00
$7.75
AVG Volume (30 Days)
1.7M
796.4K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
97.12
30.86
EPS
0.01
N/A
Revenue
$103,536,000.00
$81,357,000.00
Revenue This Year
$30.78
N/A
Revenue Next Year
$21.68
$66.49
P/E Ratio
$123.00
N/A
Revenue Growth
91.68
14.85
52 Week Low
$0.93
$0.78
52 Week High
$5.33
$4.98

Technical Indicators

Market Signals
Indicator
TYGO
ADCT
Relative Strength Index (RSI) 28.84 40.12
Support Level N/A $1.03
Resistance Level $1.73 $1.17
Average True Range (ATR) 0.16 0.07
MACD -0.01 0.02
Stochastic Oscillator 20.26 39.22

Price Performance

Historical Comparison
TYGO
ADCT

About TYGO Tigo Energy Inc.

Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: